A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment
about
A review of low-intensity ultrasound for cancer therapy.Tubulin-destabilizing agent BPR0L075 induces vascular-disruption in human breast cancer mammary fat pad xenograftsMultimodal imaging guided preclinical trials of vascular targeting in prostate cancer.Comparison of optical and power Doppler ultrasound imaging for non-invasive evaluation of arsenic trioxide as a vascular disrupting agent in tumors.Dynamic bioluminescence and fluorescence imaging of the effects of the antivascular agent Combretastatin-A4P (CA4P) on brain tumor xenografts.Evaluation of tumor ischemia in response to an indole-based vascular disrupting agent using BLI and (19)F MRI.Design, synthesis, in vitro, and in vivo anticancer and antiangiogenic activity of novel 3-arylaminobenzofuran derivatives targeting the colchicine site on tubulin.Optimization of N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines as tubulin polymerization inhibitorsCurrent and Emerging Clinical Applications of Multispectral Optoacoustic Tomography (MSOT) in OncologySynthesis and biological evaluation of N-alkyl-N-(4-methoxyphenyl)pyridin-2-amines as a new class of tubulin polymerization inhibitors.Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications.Mechanistic Considerations in the Synthesis of 2-Aryl-Indole Analogues under Bischler-Mohlau ConditionsThe vascular disrupting activity of OXi8006 in endothelial cells and its phosphate prodrug OXi8007 in breast tumor xenografts.Structural interrogation of benzosuberene-based inhibitors of tubulin polymerizationDesign, synthesis, and biological evaluation of water-soluble amino acid prodrug conjugates derived from combretastatin, dihydronaphthalene, and benzosuberene-based parent vascular disrupting agentsAn Amino-Benzosuberene Analogue That Inhibits Tubulin Assembly and Demonstrates Remarkable Cytotoxicity.N-aryl-6-methoxy-1,2,3,4-tetrahydroquinolines: a novel class of antitumor agents targeting the colchicine site on tubulin.Vascular priming enhances chemotherapeutic efficacy against head and neck cancer.Acute changes in liver tumour perfusion measured non-invasively with arterial spin labelling.Assessing Tumor Oxygenation for Predicting Outcome in Radiation Oncology: A Review of Studies Correlating Tumor Hypoxic Status and Outcome in the Preclinical and Clinical SettingsSynthesis and biological evaluation of indole-based, anti-cancer agents inspired by the vascular disrupting agent 2-(3'-hydroxy-4'-methoxyphenyl)-3-(3″,4″,5″-trimethoxybenzoyl)-6-methoxyindole (OXi8006)Synthesis of structurally diverse benzosuberene analogues and their biological evaluation as anti-cancer agents.Optimization of 4-(N-cycloamino)phenylquinazolines as a novel class of tubulin-polymerization inhibitors targeting the colchicine site.Synthesis of a 2-aryl-3-aroyl indole salt (OXi8007) resembling combretastatin A-4 with application as a vascular disrupting agentNew frontiers and developing applications in 19F NMR.Tubulin-interactive stilbene derivatives as anticancer agents.Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments.Targeted radiotherapy with gold nanoparticles: current status and future perspectives.Gold nanoparticle-aided brachytherapy with vascular dose painting: estimation of dose enhancement to the tumor endothelial cell nucleus.Pericyte-targeting prodrug overcomes tumor resistance to vascular disrupting agents.Dynamic contrast enhanced fluorescent molecular imaging of vascular disruption induced by combretastatin-A4P in tumor xenografts.Biological evaluation and molecular modelling study of podophyllotoxin derivatives as potent inhibitors of tubulin polymerization.Microenvironment-Mediated Modeling of Tumor Response to Vascular-Targeting Drugs.Vascular disrupting effect of CKD-516: preclinical study using DCE-MRI.Synthesis and Biological Evaluation of Benzocyclooctene-based and Indene-based Anticancer Agents that Function as Inhibitors of Tubulin Polymerization.Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia.Bioengineered three-dimensional co-culture of cancer cells and endothelial cells: A model system for dual analysis of tumor growth and angiogenesis.Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas.The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells.Towards dual photodynamic and antiangiogenic agents: design and synthesis of a phthalocyanine-chalcone conjugate.
P2860
Q28082093-B541FB4F-B7B0-416E-BDF0-D086B70D5F6CQ28482576-5B495AC2-99AB-4FFB-85CF-F321CB32788BQ30393012-F0FAB4F6-226A-4EEE-9BCC-7EFB24334C27Q34430810-8DF16B36-74DD-492C-831F-A31488F8E2B4Q35322855-D22D693D-4609-4B05-BCE6-6AAF9E47AA0AQ35402062-0E3F9CA9-7298-4F79-BE4A-6A111B24C45BQ35532093-A0180092-7B53-4A75-8A0E-9BCAC723C553Q36011620-226FBB06-B058-4D22-9989-4AE8E43FCD4FQ36025049-44E22411-AA6F-477B-9ADA-E4565506E117Q36536517-887D0634-0474-496B-92A4-ED26BD135379Q36609881-E77C3292-0F42-4605-8190-D3AAE17E2944Q36661964-28278315-AD0F-4249-8CAA-CCA7D56A9143Q36756648-1B1538A1-0FDA-4F98-BE7F-11B8E5B0F1EDQ36788673-58715FA8-A8A7-4F2C-888A-96BD7DE222CCQ36839418-F5A1AD04-DEAE-4401-87F0-05428D802666Q36929601-618DD618-269B-4DDA-8E11-BA4B66D87584Q37164102-BDF2E453-D0AB-489E-83B7-31F4EDE98AE5Q37169566-973C86AE-939D-4C51-8751-A9523EAE14C3Q37174704-6FF8218D-1C9A-463D-88E0-01D5597256C4Q37604088-9AE8E55B-45E1-4729-AFBD-B70650412882Q37626788-F2AF53D9-E719-44D8-BAF8-3846FDCEEB16Q37670789-001FD57F-FE2A-4C5A-BAEE-82D7AE2BF421Q37697442-5E8248DE-0203-44FB-8F66-D3D24D232F02Q37700878-A6406351-6C1F-4B2D-A7C7-AFB89554EE04Q38094240-535C03EA-699A-4DBA-9DF2-B89710AA7CACQ38118663-4A2540C2-0745-4122-B72B-43F2EE0DC1C6Q38168371-7EAEA819-8B7D-4493-8A01-70CEA81B50F1Q38224610-20EE5156-820D-4F0B-844F-C4179EF01EF1Q38435105-E3515B8B-6835-44A9-B12D-53F8C62409BFQ38941996-A3989154-09A9-4CF5-A0C4-E5674CA6C702Q38976012-3A012EED-C04E-45F3-BE3D-D65B67ACF7B2Q39137225-3F1FB3A1-AC21-43D0-9395-6A1069E2419BQ39293041-50083341-35A3-45CB-BEC0-FB097AAB4B81Q43792334-AB403D08-5999-4116-B3CD-7776EBE7BF86Q44501064-F6FDE5B2-4CC5-4748-A825-ED99F4B9E260Q48013511-C8593F2A-0812-4F00-822C-7AB686D24656Q48043061-26F437A3-5FB9-4B1B-803E-A00106B42017Q48444978-36AD5CF3-48ED-4048-9124-32391B3CC007Q49302678-E1F5F39D-E9EB-48FA-963B-DCA3312C87CDQ52620147-BC266E93-2944-4330-A005-C9E8068FB6E3
P2860
A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A perspective on vascular disr ...... ging and biological assessment
@ast
A perspective on vascular disr ...... ging and biological assessment
@en
A perspective on vascular disr ...... ging and biological assessment
@nl
type
label
A perspective on vascular disr ...... ging and biological assessment
@ast
A perspective on vascular disr ...... ging and biological assessment
@en
A perspective on vascular disr ...... ging and biological assessment
@nl
prefLabel
A perspective on vascular disr ...... ging and biological assessment
@ast
A perspective on vascular disr ...... ging and biological assessment
@en
A perspective on vascular disr ...... ging and biological assessment
@nl
P2093
P2860
P356
P1433
P1476
A perspective on vascular disr ...... ging and biological assessment
@en
P2093
Dawen Zhao
Mary Lynn Trawick
P2860
P304
P356
10.1039/C0IB00135J
P577
2011-02-14T00:00:00Z